Avoid self-medicating or combining weight loss drugs on your own, as this can increase the risk of adverse effects and may not improve your results
Still, the GLP-1 landscape can be difficult to navigate
This ultra-conservative approach adds four extra weeks to the titration timeline but can significantly reduce initial gastrointestinal symptoms, particularly for researchers who have experienced severe nausea with other GLP-1 based peptides
Tirzepatide (Mounjaro) has produced some of the largest weight-loss results seen with this class in obesity trials [9], though GI side effects can be strong early on
A double-blind, placebo-controlled trial allocated women with active IIH to 12-week dosing of either placebo ( n = 7) or exenatide ( n = 7), a GLP-1R agonist [27]
The Diabetes, Obesity and Metabolism study also found that semaglutide lowered HbA1c levels by 0.75% in people with type 2 diabetes